Richard Webster

Investigator, CHEO Research Institute

Dr. Richard Webster, has an MSc in Imaging Science and a Ph.D. in Biology. Prior to joining CHEO, he was a fellow at Health Canada working in the Genomic Laboratory of the Environmental Health Centre. Dr. Webster is now the Team Lead for Health Informatics and Big Data at the Clinical Research Unit. He contributes to the Clinical Research Unit Leadership Team, CHEO RI Data Warehouse committee, EPIC Research Application Leadership Team, as well as providing biostatistical oversight for many research projects. While based at CHEO, Dr. Webster is also a consultant for the Ontario Child Health Support Unit.

Dr. Webster’s research on child health often involves utilizing health administrative data like ICES and the CHEO RI’s data warehouse. His research interests are twofold, 1) making science more impactful and cost effective with improved statistical power analysis, and 2) improving sustainable healthcare where he collaborates with the Cochrane Climate-Health Working Group and the Centre for Sustainable Health Systems.

Related News

Research Projects

  1. Real-time detection of neonatal seizures improves with on demand EEG interpretation

    11/11/2022

    Combining aEEG with on-demand cEEG interpretation improved accurate seizure detection in a high-risk NICU population, with the potential to avoid over-treatment.

  2. Development and validation of a Fast Spine Protocol for Use in Paediatric Patients

    23/08/2022

    This study demonstrates that selected spinal imaging sequences allows for consistent and accurate diagnosis of specific clinical conditions. A limited spine protocol reduces acquisition time, potentially avoiding sedation. Further work is needed to determine the utility of selected imaging for other clinical indications.

  3. Nasopharyngeal swabs vs. saliva sampling for SARS-CoV-2 detection: A cross-sectional survey of acceptability for caregivers and children after experiencing both methods

    08/07/2022

    Though most youth find saliva sampling painless and prefer it to nasopharyngeal swabs, primary decision makers present for the experience generally remain accepting of both methods for COVID-19 testing.

  4. Incidence of chronic immune-mediated inflammatory diseases after diagnosis with Kawasaki disease: a population-based cohort study

    15/05/2022

  5. Protecting human health in a time of climate change: how Cochrane should respond

    30/03/2022